373650-12-5 Usage
Reaction
Highly active highly enantioselective catalyst for hydrogenation of functionalized ketones. The acetate salts are frequently used for hydrogenation of allyl alcohols, unsaturated carboxylic acids and reductive amination.
Asymmetric hydrogenation of substituted allyl alcohols.
Uses
(S)-Ru(OAc)2(SEGPHOS?) can be used as a catalyst: To prepare highly chemo, enantio, and diastereoselective primary β-amino lactams by asymmetric reductive amination of racemic β-keto lactams. To synthesize chiral primary diarylmethylamines and sterically bulky benzylamines from diaryl and sterically hindered ketones via asymmetric reductive amination reaction. For the conversion of levulinic acid to optically active γ-valerolactone via asymmetric hydrogenation reaction.
Check Digit Verification of cas no
The CAS Registry Mumber 373650-12-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,7,3,6,5 and 0 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 373650-12:
(8*3)+(7*7)+(6*3)+(5*6)+(4*5)+(3*0)+(2*1)+(1*2)=145
145 % 10 = 5
So 373650-12-5 is a valid CAS Registry Number.
373650-12-5Relevant articles and documents
Dynamic Kinetic Asymmetric Reductive Amination: Synthesis of Chiral Primary β-Amino Lactams
Lou, Yazhou,Hu, Yutao,Lu, Jiaxiang,Guan, Fanfu,Gong, Gelin,Yin, Qin,Zhang, Xumu
supporting information, p. 14193 - 14197 (2018/10/15)
A highly efficient ruthenium-catalyzed asymmetric reductive amination (ARA) of racemic β-keto lactams with molecular hydrogen and ammonium salts is disclosed for the synthesis of enantiomerically pure primary amino lactams through dynamic kinetic resolution (DKR). By this approach, a range of syn primary β-amino lactams were obtained in high yields with high chemo-, enantio-, and diastereoselectivity (up to 98 % yield, 99 % ee, >20:1 d.r., syn products). The utility of the products has been demonstrated by rapid access to a key synthetic intermediate towards biologically active drug molecules. Meanwhile, mechanistic studies and control experiments indicate that the reaction may proceed through the hydrogenation of an iminium intermediate.